Abstract The objective of this study was to evaluate the performance of CHROMagar Acinetobacter when compared to sheep blood agar, MacConkey agar and MacConkey agar with 6 μg/ml of imipenem for the detection of A. baumannii in surveillance cultures of hospitalized patients. We utilized peri-anal swabs and sputum samples from patients admitted to
Introduction
Acinetobacter species, especially A. baumannii, has emerged as an important nosocomial pathogen contributing to increased morbidity and mortality among infected patients [1] [2] [3] . A. baumannii causes a wide range of infections including hospital-acquired pneumonia, respiratory-tract infection, urinary tract infections, surgical site infections, and bloodstream infections [4] . Furthermore, A. baumannii is resistant to multiple classes of commonlyused antibiotics, thus complicating treatment of these infections [5] . Multiple outbreaks due to A. baumannii have been reported globally [6] [7] [8] [9] [10] [11] . These outbreaks have primarily been in intensive care units (ICUs) [7, 11] ; however, outbreaks have also occurred in surgical wards, burn units and general medical wards [6, [8] [9] [10] . Increased morbidity and mortality associated with the outbreaks have prompted some hospitals to begin performing active surveillance in high-risk patients in an attempt to control the spread of A. baumannii [12] . Currently, there is no recommended medium for screening of surveillance and clinical cultures for A. baumannii. Sheep blood agar and MacConkey agar are conventionally used for detection of A. baumannii in clinical cultures; however, these methods are non-selective for A. baumannii. Thus detection and isolation of A. baumannii from surveillance and clinical cultures is laborious and requires several days due to the presence of other bacteria species present in the human flora [13] . In contrast, chromogenic media that can rapidly identify patients colonized or infected with A. baumannii may improve the efficiency of infection control practices, shorten the time to delivery of appropriate antibiotic therapy for infected patients and reduce mortality [14] . The University of Maryland Medical Center (UMMC) utilizes an in-house selective media consisting of MacCon-key agar supplemented with 6 μg/ml of imipenem to select for multidrug resistant (MDR)-A. baumannii in surveillance cultures.
Chromogenic media are culture media that are designed for rapid and simple detection of bacteria. They contain chromogenic substrates that are cleaved by enzymes produced by bacteria resulting in unique coloration of the colonies of each bacteria strain allowing for easy identification. Currently, there are numerous chromogenic media that are commercially available and commonly used for rapid detection of colonization with organisms that cause hospital acquired infections such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, extended-spectrum beta-lactam-producing bacteria and carbapenem-resistant bacteria [15] [16] [17] [18] [19] [20] [21] .
CHROMagar Acinetobacter is a recently developed chromogenic media designed for detection and isolation of Acinetobacter species. This media inhibits the growth of most gram-positive cocci and yeast and employs a color-change identification method that allows Acinetobacter species to appear as red colonies. The objective of this study was to evaluate the performance of CHROMagar Acinetobacter when compared to sheep blood agar, MacConkey agar and MacConkey agar with 6 μg/ml of imipenem for detection and isolation of A. baumannii in infection control surveillance cultures of hospitalized patients.
Materials and methods

Sample collection
We utilized leftover peri-anal swabs and sputum samples obtained from a cohort of patients admitted to UMMC medical intensive care unit (MICU) and surgical intensive care unit (SICU) for surveillance of vancomycin-resistant enterococci from December 7, 2009 through December 21, 2009. Peri-anal swabs were obtained routinely from all patients upon ICU admission. Sputum samples were collected in sputum traps from patients who were ventilated during their ICU admission. These samples were collected as part of routine infection control surveillance; therefore, individual informed consent was not sought prior to including their samples in the study. This study was approved by the Institutional Review Board of the University of Maryland, Baltimore.
Media preparation
This study used a formulation of CHROMagar Acinetobacter that was designed for the detection of Acinetobacter species. CHROMagar Acinetobacter was prepared from dehydrated powder and liquid supplement according to manufacturer's instructions (Chromagar; Paris, France). MacConkey agar with imipenem was prepared in house from dehydrated MacConkey powder according to manufacturer's instructions (BD, Sparks, MD), and supplemented with 300 μl of 20 mg/ml stock of imipenem solution per one liter of MacConkey solution for a final concentration of 6 μg/ml. An imipenem concentration of 6 μg/ml was chosen to select for intermediate and resistant A. baumannii using Clinical and Laboratory Standard Institute (CLSI) breakpoints [22] [23] [24] . MacConkey agar and sheep blood agar plates were purchased directly from the manufacturer (BD, Sparks, MD).
Agar inoculation and comparison
Peri-anal swabs and sputum samples were inoculated directly onto the four agar media in this order: (1) 5% sheep blood agar, (2) MacConkey agar, (3) MacConkey agar with 6ug/ml of imipenem, and (4) CHROMagar Acinetobacter. The same swab was inoculated onto each media and rotated completely. Plates were streaked for isolation and incubated at 37°C for 24 hours. The same laboratory technician evaluated all four plates for a specific patient sample. CHROMagar Acinetobacter and MacConkey agar were compared to sheep blood agar for detection of Acinetobacter species, while CHROMagar Acinetobacter, MacConkey agar, and MacConkey agar with 6 μg/ml of imipenem were compared to sheep blood agar for isolation of MDRAcinetobacter. Thus, for all comparisons in this study, sheep blood agar was considered the gold standard.
Colony identification and susceptibility testing
Oxidase negative colonies morphologically similar to Acinetobacter were identified using the Vitek II (bioMerieux; Durham, NC). Susceptibilities were performed by disk diffusion method and E-tests (bioMerieux; Durham, NC) and interpreted based on current CLSI guidelines [22] . Acinetobacter isolates were tested against imipenem, doripenem, meropenem, ertapenem, sulfamethoxazoletrimethoprim, ampicillin-sulbactam, piperacillin-tazobactam, ceftazidime, cefepime, ciprofloxacin, amikacin, gentamicin, polymyxin B, and tigecycline. Multidrug resistance was defined as susceptible to two or fewer antibiotics not including polymixin B and tigecycline [24] .
Results
There were 165 surveillance samples (153 peri-anal swabs and 12 sputum samples) received at the UMMC microbiology laboratory from 165 unique patients admitted to the MICU and SICU during the 2-week study period. Only 12 sputum samples were collected due to the small number of patients ventilated during their ICU stay. Of the 165 samples collected, 17 samples (10.3%) which consisted of 12 peri-anal swabs and five sputum samples yielded Acinetobacter from sheep blood agar. One peri-anal swab yielded two morphologically different A. baumannii isolates resulting in a total of 18 Acinetobacter species isolated and identified. Of the 18 Acinetobacter isolates, 17 were identified as A. baumannii and one was identified as A. lwoffii. The two morphologically different A. baumannii isolates recovered from the same peri-anal swab had different antibiotic susceptibility profiles. One of the two isolates was identified as an MDR-A. baumannii while the other isolate was identified as a non-MDR-A. baumannii. The non-MDR-A. baumannii isolate was recovered from all four media while the MDR-A. baumannii isolate was recovered from sheep blood agar, MacConkey agar with 6 μg/ml of imipenem and CHROMagar Acinetobacter but not from MacConkey agar. On CHROMagar Acinetobacter, both isolates appeared as red colonies but the MDR-A. baumannii isolate appeared as round and smooth colonies while the non-MDR-A. baumannii isolate appeared as mucoid and spready colonies.
Sheep blood agar and CHROMagar Acinetobacter recovered 18 of 18 (100%) Acinetobacter isolates while MacConkey agar recovered 16 of 18 (89%) Acinetobacter isolates. The isolate identified as Acinetobacter lwoffii was a non-MDR-Acinetobacter and was recovered by sheep blood agar, CHROMagar Acinetobacter and MacConkey agar. Of the 18 Acinetobacter identified, 11 (61%) were identified as MDR-A. baumannii. The 11 MDR-A. baumannii were detected and isolated from eight peri-anal swabs and three sputum samples. Sheep blood agar and CHROMagar Acinetobacter recovered 11 of 11 (100%) MDR-A. baumannii. MacConkey agar recovered 10 of 11 (91%) MDR-A. baumannii. MacConkey agar with 6 μg/ml imipenem recovered 9 of 11 (82%) MDR-A. baumannii. The two MDR-A. baumannii that did not grow on MacConkey agar with 6 μg/ml imipenem had imipenem minimum inhibitory concentration (MIC) of 6 μg/ml. All MDR-A. baumannii identified were resistant to imipenem, doripenem, meropenem, ertapenem, piperacillin tazobactam and ciprofloxacin. Ten of the 11 MDR-A. baumannii (91%) were resistant to ceftazidime, 9 (82%) were resistant to ampicillin-sulbactam, 8 (73%) were resistant to amikacin, 7 (64%) were resistant to cefepime, and 5 of the 11 MDR-A. baumannii (46%) were resistant to gentamicin (Table 1) .
On CHROMagar Acinetobacter, all Acinetobacter species appeared as bright salmon-red colonies at 24 hours. Colony morphology of MDR and non-MDR-Acinetobacter was indistinguishable on CHROMagar Acinetobacter. CHROMagar Acinetobacter also allowed growth of other red colonies. These red colonies were identified as other gram-negative bacteria other than Acinetobacter and were distinguishable from Acinetobacter colonies by variation of their red color, colony morphology and oxidase reaction. Six isolates appeared as shiny red colonies, tested oxidase-positive and were identified as Pseudomonas species. Three isolates appeared as pinpoint redorange colonies with clear pheripheral edges, tested oxidase-negative and were identified as Stenotrophomonas maltophilia. Two isolates appeared as pinpoint dark red colonies, tested oxidase-positive and were identified as Achromobacter xylosoxidans (Fig. 1) .
Discussion
The objective of this study was to evaluate the performance of CHROMagar Acinetobacter when compared to sheep blood agar, MacConkey agar and MacConkey agar with 6 μg/ml of imipenem for detection and isolation of A. baumannii in infection control surveillance cultures of hospitalized patients. Sheep blood agar, an enriched media that allows for the growth of most bacterial species, was the gold standard to which all other media were compared in this study.
Our study results suggest that CHROMagar Acinetobacter was 100% sensitive for both MDR and non-MDRAcinetobacter when compared to sheep blood agar. Acinetobacter species appeared as bright salmon red colonies on CHROMagar Acinetobacter facilitating easier identification and isolation. However, CHROMagar Acinetobacter did not differentiate MDR from non-MDR-Acinetobacter and further susceptibility testing is needed to confirm multidrug resistance status. In addition, CHROMagar Acinetobacter allows growth of red colonies that were identified as other gram-negative bacteria besides Acinetobacter; however, these other bacteria could be distinguished from Acinetobacter by variation of their red color, colony morphology and oxidase reaction.
MacConkey agar was 89% sensitive for Acinetobacter species and 91% sensitive for MDR-A. baumannii when compared to sheep blood agar. It is unlikely that depletion of bacteria colonies on the inoculation swab is responsible for the Acinetobacter isolates that were not recovered by MacConkey agar since CHROMagar Acinetobacter was inoculated last and recovered all Acinetobacter isolates. MacConkey agar may be reliable for isolating Acinetobacter species but it is non-selective for Acinetobacter and does not differentiate Acinetobacter from other non-lactose fermenting gram-negative bacteria. Thus differentiating and isolating Acinetobacter from other non-lactose fermenting gram-negative bacteria on MacConkey agar may still be laborious and time-consuming.
MacConkey agar with 6 μg/ml imipenem was 82% sensitive for MDR-A. baumannii when compared to sheep blood agar. The two MDR-A. baumannii that were not recovered by MacConkey agar with 6 μg/ml imipenem had imipenem MICs of 6 μg/ml. It is possible that MDRAcinetobacter with MIC for imipenem that is close to the breakpoint for intermediate resistance may be missed with 6 μg/ml of imipenem.
Other selective media have been previously developed and compared for the detection and isolation of Acinetobacter species. Jawad et al. compared Herellea agar, Holten agar and Leeds Acinetobacter media (LAM) and reported that both Herellea agar and Holten agar have low sensitivity for Acinetobacter when compared to LAM. The study result suggested that LAM was better at selecting for and differentiating Acinetobacter from other bacteria present in the clinical and environmental samples tested. However, LAM was not commercially available in the United States during our study period and was not included in our comparative study [25] .
Previous studies have compared CHROMagar Acinetobacter to other methods for detecting Acinetobacter. Gordon et al. compared CHROMagar Acinetobacter to a molecular method for the ability to detect MDR-A. baumannii in enteric samples of critically ill patients. The CHROMagar evaluated in the study by Gordon et al. was an investigational culture media different from the one evaluated in our study. Their CHROMagar Acinetobacter contained agent that inhibits the growth of most grampositive bacteria as well as carbapenem-susceptible gramnegative bacteria while allowing Acinetobacter to appear as aqua blue colonies instead of the red colonies in our study. Their study reported that CHROMagar Acinetobacter was both sensitive (91.7%) and specific (89.7%) for MDR-A. baumannii when compared to PCR [26] .
Another study by Akers et al. evaluated CHROMagar Acinetobacter for the ability to distinguish carbepenemresistant and carbepenem-susceptible-A. baumannii. Their study reported that CHROMagar Acinetobacter was unable to distinguish carbepenem-resistant from carbepenem- [27] . The study results from Akers et al. was similar to our study result in that MDR-A. baumannii was indistinguishable from non-MDR-A. baumannii on CHROMagar Acinetobacter by colony color or morphology. In our study, S. maltophilia, P. aeruginosa and A. xylosoxidans grew on CHROMagar Acinetobacter with a similar red color as A. baumannii but we did not observe the growth of E. cloacae and S. aureus as reported by Akers et al. This study also reported a lower sensitivity of CHROMagar Acinetobacter for A. baumannii than observed in our study.
CHROMagar Acinetobacter has been recently improved to select for MDR-Acinetobacter. Addition of an optional MDR supplement CR102 specifically selects for MDRresistant strains defined as strains that are resistant to carbapenems. CHROMagar Acinetobacter specifically designed for identification of MDR-Acinetobacter was recently evaluated by Wareham et. al. This study reported that the addition of the MDR supplement to CHROMagar Acinetobacter prevented the growth of carbapenemsusceptible A. baumannii. However, the authors reported that S. maltophilia still grew on CHROMagar Acinetobacter and appeared with a similar red color as A. baumannii, making it difficult to distinguish from A. baumanii [28] .
Excluding the cost of equipment and labor, the cost of CHROMagar Acinetobacter is higher than the cost of sheep blood agar and MacConkey agar. However, there may be additional costs associated with isolation and identification of other bacterial isolates worked up and ultimately found not to be Acinetobacter when using sheep blood agar and MacConkey agar. CHROMagar Acinetobacter may save time when the absence of a red color indicates the absence of Acinetobacter species in a patient sample. However, a comprehensive time and cost-benefit analysis of using CHROMagar Acinetobacter versus sheep blood agar and MacConkey agar for isolating Acinetobacter is beyond the scope of this study. It will be useful for future studies to compare CHROMagar Acinetobacter to other culture media on their time and cost savings.
In summary, our study results and those from prior studies suggest that CHROMagar Acinetobacter is selective for A. baumannii but still allows growth of certain other gram-negative bacteria with a similar red color as A. baumannii. Even though these other bacteria can be distinguished from Acinetobacter by the variation of their red color, colony morphology and oxidase reaction, there is still need for CHROMagar Acinetobacter to better differentiate A. baumannii from these other gram-negative bacteria without further testing to confirm A. baumannii. CHROMagar Acinetobacter may be a useful media for screening and improving infection control strategies aimed at limiting the spread of MDR-A. baumannii if improved upon to better select for MDR-A. baumannii. The addition of MDR supplement to CHROMagar Acinetobacter has demonstrated selectivity for carbapenem-resistant A. baumannii. However, larger studies in different patient populations are needed to evaluate the performance of CHROMagar Acinetobacter with MDR supplement for screening of MDR-A. baumannii. Although a limitation of this study is the small sample size, this study provides useful information on the performance of CHROMagar Acinetobacter when compared to other culture media for detection of A. baumannii for surveillance and control of Acinetobacter species in critically ill patients.
